Edwards Lifesciences delivered a strong Q3 2025 performance, with sales growing 12.6% year-over-year to $1.55 billion, driven by double-digit growth in TAVR and a 53% surge in TMTT sales. Adjusted EPS reached $0.67, significantly beating expectations, prompting the company to raise full-year sales growth guidance to the high end of 9-10% and EPS guidance to $2.56-$2.62. Key drivers included robust TAVR sales of $1.15 billion (+10.6%), bolstered by new 7-year durability data from the PARTNER III trial and updated clinical guidelines favoring earlier intervention. Management expressed high confidence in sustainable growth into 2026, citing a comprehensive structural heart portfolio and upcoming product launches like SAPIEN M3, despite the announced departure of CFO Scott Ullem by mid-2026.
| Metric | Value | Change |
|---|---|---|
| Sales | $1.55 billion | +12.6% |
| TAVR Sales | $1.15 billion | +10.6% |
| TMTT Sales | $144 million | +53% |
| Surgical Sales | $258 million | +5.6% |
| Adjusted EPS | $0.67 | Above expectations |
| Adjusted Gross Margin | 77.9% | -280 bps YoY |
| Adjusted Operating Margin | 27.5% | Driven by top line |
Edwards is leveraging its unparalleled clinical data to solidify a defensive moat around its TAVR franchise. The presentation of 7-year PARTNER III and 10-year PARTNER II data confirms SAPIEN's durability is comparable to surgery, effectively removing the last major barrier for TAVR adoption in younger, low-risk patients. This 'unprecedented body of evidence' allows Edwards to dictate the standard of care, forcing competitors to match their clinical outcomes, and supports the strategic shift towards treating asymptomatic patients earlier.
The company is successfully executing a multi-vector growth strategy by rapidly scaling its TMTT (Transcatheter Mitral and Tricuspid Therapies) portfolio. With TMTT sales surging 53% to $144 million, driven by EVOQUE and PASCAL, Edwards is proving it can replicate its TAVR success in new valve markets. The upcoming U.S. launch of SAPIEN M3 for mitral replacement in early 2026 represents a significant catalyst, targeting patients who are unsuitable for TEER or surgery, thereby expanding the total addressable market.
Management is actively driving a paradigm shift in clinical practice through guideline updates and educational initiatives. The new ESC/EACTS and American Society of Echocardiography guidelines recommend urgent intervention for severe aortic stenosis rather than 'watchful waiting.' By aligning its commercial strategy with these updated guidelines and investing in AI-driven screening tools, Edwards is positioning itself to capture a larger volume of the untreated patient population.
Edwards is prioritizing capital allocation towards shareholder returns and innovation while maintaining financial flexibility. The company repurchased over $800 million of stock year-to-date and has $2 billion remaining in authorization, signaling confidence in cash flow generation. Simultaneously, R&D spending remains disciplined (18.1% of sales), focused on high-growth areas like structural heart, ensuring that top-line growth outpaces R&D expense growth to drive margin expansion.
The operational focus is shifting towards efficiency and capacity creation to handle anticipated demand growth. Management highlighted 'Benchmark' programs and AI initiatives aimed at reducing cath lab times and improving patient identification. This investment in commercial infrastructure is critical for converting the 'renewed focus' from physicians into sustained procedure volume, ensuring that the clinical halo from TCT translates into market share gains.
The announcement of CFO Scott Ullem's transition out of the company by mid-2026 introduces a layer of uncertainty. While Ullem will remain as a strategic adviser, the loss of a 12-year veteran who has been instrumental in the company's financial strategy could disrupt investor confidence or lead to shifts in capital allocation priorities during the search for a successor.
Edwards faces significant regulatory and legal risks regarding the JenaValve acquisition. The FTC has blocked the deal, and a scheduled trial is set for Q1. While management expressed confidence in a 'favorable ruling,' a negative outcome would block their entry into the aortic regurgitation market, result in sunk costs, and force them to rely solely on organic pipeline solutions like SAPIEN X4.
Despite the strong quarter, management warned that the exceptional 10.6% TAVR growth was aided by a lack of summer seasonality and 'halo' effects from conferences, explicitly stating 'I will not take the Q3 results as the new normal.' Investors should be wary of assuming this specific growth rate will persist sequentially without the full materialization of new indications or policy changes.
Foreign exchange (FX) headwinds are pressuring margins, with FX rates negatively impacting the third-quarter gross profit margin by 110 basis points. Management guided for a lower Q4 operating margin in the mid-20% due to the timing of investments and continued FX pressure, requiring higher sales growth to maintain the company's long-term margin expansion targets.
Overall: Management exhibited a highly confident and assured demeanor throughout the call, frequently emphasizing the strength of their clinical evidence and the 'renewed focus' from the medical community. Bernard Zovighian was particularly bullish on the long-term durability of their TAVR platform and the multi-year growth opportunity, while Scott Ullem maintained a steady, factual tone during financial discussions, even while announcing his departure.
Confidence: HIGH - Management consistently used definitive language regarding their market leadership and product durability ('proven at 7 years', 'sets a new global benchmark'). They raised guidance confidently and dismissed concerns about Q3 seasonality being the 'new normal' while maintaining long-term targets.
High end of 9% to 10%
$2.56 to $2.62
7% to 8%
$530 million to $550 million
$1.51 billion to $1.59 billion
$0.58 to $0.64
Hedging & Uncertainty: Management generally avoided heavy hedging regarding their core business, using strong, definitive verbs ('confirm', 'demonstrated', 'proven') to describe clinical data. However, they employed temporal hedging regarding the JenaValve trial ('we will know in Q1') and the specific impact of asymptomatic patient adoption ('we don't see any specific evidence of that'). Scott Ullem used probabilistic language regarding FX impacts ('we continue to expect FX to have an approximately $30 million upside'), acknowledging the inherent volatility of currency markets while maintaining a positive outlook.
The results confirm that rates of all-cause mortality for TAVR remain low and comparable to the surgical control arm. - Bernard Zovighian, CEO
We are raising full year sales growth guidance to the high end of a previous 9% to 10% range. - Bernard Zovighian, CEO
I will not take the Q3 results as the new normal for TAVR. - Bernard Zovighian, CEO
We remain committed to annual constant currency operating profit margin expansion over the full year 2025 level in 2026 and beyond. - Scott Ullem, CFO
We believe here we have great facts. At the same time, we will know in Q1. - Bernard Zovighian, CEO
Analyst Sentiment: Analysts were highly inquisitive about the sustainability of the TAVR beat and the mechanics of the M3 launch. Questions were focused and constructive, probing the 'new normal' for TAVR and the competitive landscape following the clinical data releases.
Management Responses: Management was responsive and detailed, often deferring to divisional leaders (Dan Lippis, Daveen Chopra) for technical clinical questions. They maintained a disciplined approach to guidance, refusing to get ahead of themselves on 2026 specifics while reiterating confidence in long-term targets.
Analysts pressed for details on the underlying TAVR trends, specifically asking if the 10.6% growth was sustainable or an anomaly due to lack of seasonality. Management clarified that while Q3 was exceptional, the 'big catalysts' like asymptomatic treatment are still ahead.
Discussion focused heavily on the competitive implications of the 7-year and 10-year durability data presented at TCT. Management emphasized that this data sets a 'new global benchmark' and reassures physicians regarding long-term valve performance.
Questions regarding the SAPIEN M3 launch strategy compared to EVOQUE. Management highlighted a controlled, high-training launch in Europe focused on 'unsuitable' patients to ensure optimal outcomes.
Inquiries about the JenaValve litigation timeline and the SAPIEN X4 pipeline. Management remained tight-lipped on X4 data but expressed confidence in the legal process for JenaValve.
Edwards Lifesciences is executing flawlessly on its structural heart strategy. The Q3 beat and subsequent guidance raise demonstrate the power of their clinical data to drive market share and volume. The 7-year durability data effectively neutralizes the primary risk to the TAVR franchise, while the rapid scaling of TMTT (EVOQUE, PASCAL, M3) provides a high-growth second leg to the stool. Although the CFO transition introduces near-term noise, the fundamental business momentum is undeniable. The company is successfully converting clinical excellence into commercial dominance, justifying a premium valuation.
Updates to ESC/EACTS and ASE guidelines are shifting the standard of care towards earlier intervention for aortic stenosis, moving away from 'watchful waiting' to urgent treatment.
Exit of a competitor (implied Boston Scientific) in Europe contributed to market share gains, though management characterized the contribution as 'modest'.
FX rates negatively impacted gross margins by 110 basis points in Q3, though the company's hedging program mitigates the impact on EPS.